The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults.
Saved in:
| Title: | The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults. |
|---|---|
| Authors: | Whitaker JA; Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, TX, USA., Rebolledo PA; Hope Clinic, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA; Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA., Abate G; Center for Vaccine Development, Division of Infectious Diseases, Allergy and Immunology, Departments of Internal Medicine, Saint Louis University, Saint Louis, MO, USA., Babu TM; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA., Rouphael NG; Hope Clinic, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA., Wald A; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., El Sahly HM; Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, TX, USA., Jooss K; Gritstone bio, Inc. Emeryville, CA, USA., Hart MG; Gritstone bio, Inc. Emeryville, CA, USA., Makowski M; The Emmes Company, LLC, Rockville, MD, USA., Mu J; The Emmes Company, LLC, Rockville, MD, USA., Carmack A; The Emmes Company, LLC, Rockville, MD, USA., Archer JI; FHI 360, Durham, NC, USA., Roberts PC; Division of Microbiology and Infectious Diseases, NIAID, NIH, Rockville, MD, USA., Makhene M; Division of Microbiology and Infectious Diseases, NIAID, NIH, Rockville, MD, USA., Posavad CM; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., McElrath MJ; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., De Rosa SC; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Coler R; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, USA., Montefiori D; Department of Surgery, Duke University Medical Center, Durham, NC, USA; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Eaton A; Department of Surgery, Duke University Medical Center, Durham, NC, USA; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Suthar MS; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30329, USA., Atmar RL; Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX, USA., Hoft DF; Center for Vaccine Development, Division of Infectious Diseases, Allergy and Immunology, Departments of Internal Medicine, Saint Louis University, Saint Louis, MO, USA; Department of Molecular Microbiology & Immunology, Saint Louis University, Saint Louis, MO, USA. Electronic address: daniel.hoft@slu.edu. |
| Corporate Authors: | DMID 20-0034 Study Team |
| Source: | Vaccine [Vaccine] 2026 Apr 02; Vol. 77, pp. 128358. Date of Electronic Publication: 2026 Feb 25. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
